Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

被引：0
|
作者：
Bardia, A.
Diamond, J. R.
Mayer, I. A.
Isakoff, S. J.
Abramson, V.
Starodub, A. N.
O'Shaughnessy, J.
Kalinsky, K.
Moroose, R.
Shah, N.
Juric, D.
Shapiro, G. I.
Guarino, M.
Ocean, A. J.
Messersmith, W. A.
Berlin, J. D.
Wegener, W. A.
Sharkey, R. M.
Goldenberg, D. M.
Vahdat, L. T.
机构：
[1] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Canc, Boston, MA 02114 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Indiana Univ, Hlth Ctr Canc Care, Goshen, IN USA
[5] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[6] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[7] Univ Florida, Hlth Canc Ctr, Orlando, FL USA
[8] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA
[9] Helen F Graham Canc Ctr, Newark, DE USA
[10] Weill Cornell Med, New York, NY USA
[11] Immunomed Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-22-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-22-15
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Messersmith, Wells A.
    Mayer, Ingrid A.
    Isakoff, Steven J.
    Abramson, Vandana Gupta
    Berlin, Jordan
    Starodub, Alexander
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Moroose, Rebecca L.
    Shah, Nikita C.
    Juric, Dejan
    Shapiro, Geoffrey
    Guarino, Michael J.
    Ocean, Allyson J.
    Wilhelm, Francois
    Sharkey, Robert M.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [2] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Tolaney, Sara M.
    Santin, Alessandro D.
    Abramson, Vandana
    Shah, Nikita C.
    Govindan, Serengulam V.
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Mayer, Ingrid A.
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer Robinson
    Starodub, Alexander
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Ocean, Allyson J.
    Berlin, Jordan
    Messersmith, Wells A.
    Thomas, Sajeve Samuel
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Goldenberg, David M.
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Vahdat, Linda T.
    Isakoff, Steven J.
    Guarino, Michael
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Mayer, Ingrid A.
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER, 2017, 123 (19) : 3843 - 3854
  • [5] Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
    Camidge, D. Ross
    Heist, Rebecca Suk
    Masters, Gregory A.
    Scheff, Ronald J.
    Starodub, Alexander
    Messersmith, Wells A.
    Bardia, Aditya
    Ocean, Allyson J.
    Horn, Leora
    Berlin, Jordan
    Maliakal, Pius P.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
    Guarino, Michael J.
    Starodub, Alexander
    Masters, Gregory A.
    Heist, Rebecca Suk
    Messersmith, Wells A.
    Bardia, Aditya
    Ocean, Allyson J.
    Thomas, Sajeve Samuel
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Starodub, Alexander N.
    Shah, Nikita C.
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Guarino, Michael
    Abramson, Vandana
    Juric, Dejan
    Tolaney, Sara M.
    Berlin, Jordan
    Messersmith, Wells A.
    Ocean, Allyson J.
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +
  • [8] Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).
    Tagawa, Scott T.
    Ocean, Allyson J.
    Lam, Elaine Tat
    Saylor, Philip James
    Bardia, Aditya
    Hajdenberg, Julio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
    Goldenberg, David M.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Rossi, Edmund A.
    Sharkey, Robert M.
    ONCOTARGET, 2015, 6 (26) : 22496 - 22512
  • [10] Treatment for metastatic platinum resistant urothelial cancer (PRUC) with an anti-Trop2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
    Tagawa, Scott T.
    Faltas, Bishoy
    Lam, Elaine
    Messersmith, Wells A.
    Saylor, Philip
    Bardia, Aditya
    Hajdenberg, Julio J.
    Morgans, Alicia K.
    Berlin, Jordan D.
    Lim, Emerson
    Kalinsky, Kevin
    Maliakal, Pius
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Ocean, Allyson J.
    CANCER RESEARCH, 2016, 76
12345